About US
Contact us
-
AstraZeneca settles lingering China bribery case with SECAstraZeneca has often been pointed to as a company that knows how to succeed in emerging markets like China, and CEO Pascal Soriot has made growth in these areas as one element of in his 5-part growth2016/9/22
-
Mylan faces more EpiPen scrutiny as House committee demands infoIf Mylan was hoping that its new EpiPen copay assistance and authorized generic would stave off government probing, then it’s hoping in vain. Another congressional commitee has piled on to Mylan and2016/9/21
-
AG lambasts Purdue for fighting his opioid marketing probePurdue Pharma’s highly addictive opioid Oxycontin has led to the company beingmaligned in lawsuits, by law enforcement officials and state and federal lawmakers. Now the Attorney General of New Hampsh2016/9/21
-
Insys sued by Illinois AG for off-label marketing of Subsys opioid sprayAfter a former Insys Therapeutics ($INSY) sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for off-label uses, it was just a matter o2016/9/20
-
Celgene off-label marketing lawsuit documents unsealedCelgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing.A California2016/9/20
-
Hillary's latest drug-price tweet put the fear of government action into biopharma stocksThe power of a Hillary Clinton tweet was proven again Wednesday, when the presidential candidate sent out a missive about drug prices. Biotech stocks, down. Pharma stocks, down. Even U.K. drugmakers s2016/9/19
-
With patent strikedown, Teva's new Copaxone formula loses two defenses against genericsBad news for Teva, much-needed good news for the embattled Mylan: The U.S. Patent and Trademark office’s review board struck down two patents on Teva’s new long-acting multiple sclerosis med Copaxone.2016/9/19
-
Novartis bankers assembling big investors for $14B Roche stake sale: HandelszeitungNovartis ($NVS) is getting closer to unloading its $14 billion stake in crosstown rival Roche ($RHHBY). According to areportthis week in the Zurich newspaperHandelszeitung, big investors have been sho2016/9/14
-
Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy?It’s been a busy week for Pfizer. Fresh off its $14 billion deal for Medivation, the drug giant is snapping up a portfolio of AstraZeneca antibiotics for up to $1.5 billion--a portfolio that just happ2016/9/14
-
Investors bid up post-Medivation M&A targets BioMarin, Incyte and moreWhen one M&A door closes, many potential windows open. At least that was the operative theory Mondayafter Pfizer ($PFE) said it had wrapped up a $14 billion deal for Medivation ($MDVN), leaving a2016/9/13